Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.
about
Disease-modifying treatments for multiple sclerosis - a review of approved medicationsStage-specific immune dysregulation in multiple sclerosisClinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets.Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature.Issues and practices in multiple sclerosis.Recent developments in multiple sclerosis therapeuticsBiomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.Imaging of multiple sclerosis: role in neurotherapeutics.MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.Emerging therapies in multiple sclerosis.Childhood multiple sclerosis: a review.Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.Progressive multiple sclerosis: from pathogenic mechanisms to treatment.Central nervous system atrophy and clinical status in multiple sclerosis.Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments.Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?Monoclonal antibody treatments for multiple sclerosis.Black holes in multiple sclerosis: definition, evolution, and clinical correlations.Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes.Drug treatment of multiple sclerosisTreating multiple sclerosis with monoclonal antibodies: a 2013 update.Chemotherapeutics in the treatment of multiple sclerosis.Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS.Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies.Monoclonal antibodies in the therapy of multiple sclerosis: an overview.Magnetic resonance imaging of multiple sclerosis.Axonal damage in multiple sclerosis.Clinical trials in progressive multiple sclerosis: lessons learned and future perspectivesSpinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.The pathogenesis of multiple sclerosis: is it really a primary inflammatory process?Measurement of spinal cord atrophy in multiple sclerosis.Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy.Brain atrophy in multiple sclerosis: what we know and would like to know.Toward the development of rational therapies in multiple sclerosis: what is on the horizon?New developments in understanding and treating neuroinflammation.Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.Disease-modifying agents for multiple sclerosis: recent advances and future prospects.Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus
P2860
Q26777329-584ACE36-31A9-4F97-A932-4F9A89F09181Q26852859-DC7269E7-2DB4-4F87-9C54-0E61CC0A1F53Q30640097-C4E8AABF-F0AD-45AF-8F33-9C6022E772B4Q30739162-B2CBA266-8B91-4750-A0FA-78FD160A817CQ30751454-CE3ED8BC-9056-416A-AD3C-41CADB74CF83Q30962193-707C092D-914E-4368-8EC1-8E7166C3C2D2Q30983016-CE978DCE-D65B-4475-BA23-9DC00784E9CDQ30989935-A8DFBAF8-4D94-4A76-B0C0-8E1786CF46E1Q31014025-3C68C09E-F278-4715-A19A-D51D7F913F49Q31015100-F4B0DA82-BBE3-4CB3-A2BD-4842B1C0F411Q31047410-5F3ECDF3-F278-4FBA-91BB-675882FF6107Q31070072-5B490989-9A0C-46BE-ACA9-AC4F147CC833Q31139925-4B31DC59-6E14-4B51-8EF1-1AE487E0B25DQ33204392-BAA81893-D753-44DB-BE41-3D62CBC9C17CQ33204393-73E06B02-CC65-406A-84BB-DFC717DA8EC1Q33214417-58C1AAFB-6CA9-4357-AB77-72AB762D474FQ33289264-8F7AB4BE-6928-4D34-842C-6D2A67432D22Q33380819-DE0C3C33-F25F-4219-A668-E43187946B80Q33517838-F580FD4B-D338-482B-B537-1A8B012F9194Q33855341-4781E7AD-2F2E-4C74-A786-D1B9662BF372Q34007633-DC3F4250-D4F9-443B-9D6F-C7FF9F425827Q34330211-6323BD88-8C7B-46C2-B9A7-AF2A33E0BE61Q34409536-0D4C08C3-64E8-4C0F-A076-F32A8BC98399Q34465422-1C316650-AF95-4F73-96DA-05E5B2526F4BQ34590775-F48DEDD3-F29D-4995-A6F5-4EE00BF4C8ECQ34605605-DEC5B570-71C8-4FCA-9BF1-B2AC82CCA4C9Q34965696-756E712C-08D1-4EB1-997C-E807CE62FD1BQ35126104-4E03D66D-3FDC-4DE8-B46A-B0610171C6E7Q35182733-1EFC861C-3305-4C02-AC57-0FD6C37888A9Q35475689-6030C30A-0D48-4300-B63D-AB5FD2B7BEC6Q35607258-E55F9148-D198-4149-AC3F-D7BE719372BFQ35820295-C4AB2134-3E91-40EC-84A1-C1669FFC61EBQ35823716-80FBB276-1A38-4B6B-A336-2F4464155054Q35823723-B8CF9041-0CF1-4278-B552-D6DCBBB326CFQ36722172-499DF248-58C7-4762-9985-B3E19B081400Q36985173-D370CF79-3A60-47C4-8A19-2DC572C75DB3Q37057309-11EF81E1-161F-4279-B7EC-55EDE9FE2184Q37142971-03EF80AD-F071-437A-85FA-68CDEA594A6CQ37328280-11A671E1-7A02-4F58-AE90-9B4C94CB3E5DQ37613091-90FD2DD1-DB80-41D2-9A60-F62562EEE732
P2860
Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Quantitative MRI in patients w ...... onoclonal antibody Campath 1H.
@ast
Quantitative MRI in patients w ...... onoclonal antibody Campath 1H.
@en
type
label
Quantitative MRI in patients w ...... onoclonal antibody Campath 1H.
@ast
Quantitative MRI in patients w ...... onoclonal antibody Campath 1H.
@en
prefLabel
Quantitative MRI in patients w ...... onoclonal antibody Campath 1H.
@ast
Quantitative MRI in patients w ...... onoclonal antibody Campath 1H.
@en
P2093
P356
P1433
P1476
Quantitative MRI in patients w ...... onoclonal antibody Campath 1H.
@en
P2093
A Paolillo
D A Compston
D H Miller
G J Barker
M Gawne-Cain
P D Molyneux
P304
P356
10.1212/WNL.53.4.751
P407
P577
1999-09-01T00:00:00Z